Acquisition Opportunity MedAlliance was acquired by Cordis for up to 1.135B, indicating strong strategic value and potential channel integration. Explore joint go-to-market plans, leverage Cordis distribution networks, and align on combined product roadmaps to accelerate adoption of SELUTION SLR.

Global Footprint Headquartered in Switzerland with offices in Germany, Singapore, the UK, and the USA, MedAlliance has an international presence conducive to cross-border sales. Target multi-region hospitals and vascular centers, emphasizing global regulatory readiness and regional clinical evidence to support expansion.

Clinical Momentum Landmark trials and rapid patient enrollment for SELUTION SLR, including DeNovo and LOVE-DEB studies, demonstrate strong clinical demand. Leverage ongoing trial data to engage key opinion leaders and hospitals evaluating new drug-eluting balloon solutions.

Regulatory Track Record Breakthrough Device Designation history and CE Mark approvals for peripheral and coronary indications show regulatory proficiency. Position SELUTION SLR as a compliant, accelerated access option, appealing to hospitals seeking faster revenue generation from innovative devices.

Pricing and Promotion Significant funding activity and a high-profile acquisition signal financial backing and potential pricing leverage. Propose bundled procurement or milestone-based pay structures with Cordis, and present value propositions around long-term cost savings from reduced restenosis and repeat interventions.